NASDAQ : RNAC
Cartesian Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 204.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 196.36M |
| Enterprise Value | 112.60M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 30.26M |
| Shares Outstanding | 30.26M |
| Shares Change (YoY) | +9.55% |
| Shares Change (QoQ) | +11.35% |
| Owned by Insiders (%) | 53.31% |
| Owned by Institutions (%) | 21.55% |
| Float | 11.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 132.94 |
| Forward PS | 445.78 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 76.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.48 |
| Quick Ratio | 7.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -115.80 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -17.43% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -33.10% |
| Weighted Average Cost of Capital (WACC) | 6.46% |
| Revenue Per Employee | $19,693 |
| Profits Per Employee | -$2.03M |
| Employee Count | 75 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -9.19M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -20.85% |
| 50-Day Moving Average | 7.74 |
| 200-Day Moving Average | 7.65 |
| Relative Strength Index (RSI) | 41.88 |
| Average Volume (20 Days) | 134,651 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.88M |
| Short Previous Month | 1.86M |
| Short % of Shares Out | 6.20% |
| Short % of Float | 16.32% |
| Short Ratio (days to cover) | 12.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.48M |
| Gross Profit | -66.91M |
| Operating Income | -98.66M |
| Pretax Income | -161.08M |
| Net Income | -151.89M |
| EBITDA | -96.05M |
| EBIT | -98.66M |
| Loss Per Share | -$5.61 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 147.61M |
| Total Debt | 63.85M |
| Net Cash | 83.75M |
| Net Cash Per Share | $2.77 |
| Equity (Book Value) | -125.23M |
| Book Value Per Share | -4.17 |
| Working Capital | 133.07M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -76.53M |
| Capital Expenditures | -2.08M |
| Depreciation & Amortization | 2.61M |
| Net Borrowing | 46.03M |
| Free Cash Flow | -78.61M |
| FCF Per Share | -$2.60 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -6,679.69% |
| Pretax Margin | -10,906.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.55% |
| Shareholder Yield | -9.55% |
| Earnings Yield | -86.47% |
| FCF Yield | -40.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.67 |
| Price Target Difference | 418.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 99.02% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.93 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |